Always private
DuckDuckGo never tracks your searches.
Learn More
You can hide this reminder in Search Settings
All regions
Argentina
Australia
Austria
Belgium (fr)
Belgium (nl)
Brazil
Bulgaria
Canada (en)
Canada (fr)
Catalonia
Chile
China
Colombia
Croatia
Czech Republic
Denmark
Estonia
Finland
France
Germany
Greece
Hong Kong
Hungary
Iceland
India (en)
Indonesia (en)
Ireland
Israel (en)
Italy
Japan
Korea
Latvia
Lithuania
Malaysia (en)
Mexico
Netherlands
New Zealand
Norway
Pakistan (en)
Peru
Philippines (en)
Poland
Portugal
Romania
Russia
Saudi Arabia
Singapore
Slovakia
Slovenia
South Africa
Spain (ca)
Spain (es)
Sweden
Switzerland (de)
Switzerland (fr)
Taiwan
Thailand (en)
Turkey
Ukraine
United Kingdom
US (English)
US (Spanish)
Vietnam (en)
Safe search: moderate
Strict
Moderate
Off
Any time
Any time
Past day
Past week
Past month
Past year
Showing results excluding:
  • dementianetwork.ie

All Results

  1. PMSMatTrain focuses on gaining a comprehensive understanding of the progressive phase of multiple sclerosis (PMS) from basics to translation, fully supported by eight beneficiaries (six research institutions and two SMEs). ... will receive compulsory discipline-specific, generic and complementary training. The PMSMatTrain's Joint Research ...
  2. PMSMatTrain focuses on gaining a comprehensive understanding of the progressive phase of multiple sclerosis (PMS) from basics to translation, fully supported by eight beneficiaries (six research institutions and two SMEs). ... 15 Early Stage Researchers in functionalised biomaterials, materials science, stem cell biology, pre-clinical models ...
  3. Bhavya Ojha obtained her BSc in Neuroscience from Dalhousie University, Canada, and an MSc in Molecular bioscience (majors: Neuroscience) from Heidelberg University, Germany.Her MSc thesis focused on impact of chronic neuropathic pain on attention in mice. In the PMSMatTrain project, her research focuses on progressive multiple sclerosis and assessing potential therapy delivered via novel routes.
  4. curamdevices.ie

    Novel Biomaterial-based Device for the Treatment of Progressive MS. An Integrated Pan-European Approach ‌‌‌ Overview of the Programme . PMSMatTrain focuses on gaining a comprehensive understanding of the progressive phase of multiple sclerosis (PMS) from basics to translation, fully supported by eight beneficiaries (six research institutions and two SMEs).
  5. cordis.europa.eu

    Oct 28, 2024PMSMatTrain. Grant agreement ID: 813263 Open in new window Project website DOI 10.3030 ... Longitudinal evaluation of the therapeutic effect of APRIL in the Cuprizone mouse model of Multiple Sclerosis. Author(s): Leonardo Ricciardi, Marion Decrop, Joëlle ... Molecular Research in Multiple Sclerosis Author(s): ...
  6. ncbi.nlm.nih.gov

    National Center for Biotechnology Information

    https://www.ncbi.nlm.nih.gov › pmc › articles › PMC8911110

    Therefore, a single molecular marker is unlikely to exist, and efforts on molecular research in multiple sclerosis should be made towards integrating analytic approaches, including clinical characteristics, MRI variables and proteins, and metabolite concentrations to create signatures of MS disease diagnosis, prognosis, and treatment response.
  7. pmc.ncbi.nlm.nih.gov

    Importantly, numerous molecular and cellular mechanisms of MS pathogenesis have been discovered in EAE research (36, 91, 251, 460). New EAE variants are also emerging, and they are exploring aspects of MS that were previously unaddressed in animal models, for example, the role of CD8 + T cells in neuroinflammation ( 14 , 225 ).
  8. The mechanisms underlying the pathogenesis of multiple sclerosis induce the changes that underpin relapse-associated and progressive disability. Disease mechanisms can be investigated in preclinical models and patients with multiple sclerosis by molecular and metabolic imaging techniques. Many insights have been gained from such imaging studies: persisting inflammation in the absence of a ...
  9. pubmed.ncbi.nlm.nih.gov

    CNS biological processes reflected by CSF biomarkers are robust, stable, disease specific, or even disease stage specific. This opens opportunities for broad utilization of CSF biomarkers in drug development and precision medicine for CNS disorders. Ann Neurol 2017;82:795-812.

    Can’t find what you’re looking for?

    Help us improve DuckDuckGo searches with your feedback

Custom date rangeX